Research on stem cells and regenerative medicine. Covers engineered T cells, scalable manufacturing, blood-cancer research, and stem-cell training programs.
Researchers at the University of Sydney developed a computational framework to evaluate the biological accuracy of lab-grown human embryo models. The study found that while some models perform well, none yet fully capture the complexity of early human development.
Mount Sinai researchers identified how APOE4 damages brain blood vessels, promoting abnormal protein buildup and neurodegeneration. They found that blocking TGF-β signaling restored pericyte coverage, reducing fibrosis and vascular amyloid accumulation.
Researchers aim to understand the conditions that determine the survival of transplanted retinal cells and develop more effective regenerative therapies for geographic atrophy. They also seek to uncover early mechanisms that contribute to infertility and create a more detailed blueprint for human germ cell development.
A UCLA research team engineered immune cells that target atherosclerotic plaques, clearing out rogue smooth muscle cells and inflamed macrophages and foam cells. The 'triple-threat' cells outperformed single-target versions in mouse models and artery tissue, showing promise in treating cardiovascular disease.
The journal welcomes leading researchers with expertise in hematopoietic and muscle stem cell biology, advancing understanding of stem cell research in health and disease. Drs. Bonnet and Relaix bring significant breadth of expertise and commitment to rigorous science, enhancing Stem Cell Reports' impact.
UCLA scientists develop a stem cell-based platform to produce uniform T cells that target solid tumors in a unique way, avoiding a common side effect. The therapy, called AlloESO-T cells, keeps tumors in check and extends survival in mouse models of ovarian, melanoma, and prostate cancers.
Researchers at Boston Medical Center and Boston University have developed a scalable method for generating CD4+ helper T cells from induced pluripotent stem cells (iPSCs), overcoming a longstanding challenge in the development of stem cell-based immunotherapies. This breakthrough could help advance efforts to create off-the-shelf CAR-T...
Dr. Georg Aue, a nationally recognized blood cancer expert, has been named the inaugural director of the Stem Cell Transplant and Cellular Therapy Program at UT Health San Antonio. The program aims to increase access to new therapeutic approaches for patients across South Texas, with a focus on clinical excellence, research innovation,...
The DKMS John Hansen Research Grant supports innovative cell therapy approaches and transplant immunology. The grant enables young researchers to build a network and advance lifesaving therapies for blood cancer.
Dr. Lorenz Studer is known for his pioneering advances in stem cell biology, regenerative medicine, and the development of stem cell-based therapies for neurodegenerative disease.
The Marcus Foundation has awarded $28.7 million to advance a clinical trial testing a stem cell-based therapy designed to regenerate damaged heart tissue after a heart attack. Researchers aim to develop approaches that could reduce or eliminate the need for immunosuppressive drugs.
A new study investigates the efficacy of stem cell injections for treating knee osteoarthritis, finding that MSC potency can be predicted through lab-based tests. Patients who showed improved pain and mobility scores had MSCs with enhanced anti-inflammatory effects.
A new study found that children preparing for stem cell transplantation already have subtle respiratory abnormalities, including increased small-airway resistance and greater lung stiffness. These abnormalities are likely related to their underlying disease or previous therapies rather than the transplant itself.
Scientists have discovered that TRF2, a protein previously known for protecting chromosome ends, plays a crucial role in preserving the identity of muscle stem cells and enabling their regenerative abilities. This new understanding may lead to the development of therapeutic strategies for muscular dystrophy and cancer research.
The Alliance QUANTUM trial is testing whether post-transplant consolidation therapy with teclistamab improves survival in patients with primary plasma cell leukemia. Plasma cell leukemia is a rare but aggressive blood cancer with poor long-term survival rates.
The International Society for Stem Cell Research (ISSCR) has recognized five outstanding researchers for their innovative work on developmental biology, disease modeling, regenerative medicine, and functional genomics. The award winners were selected from over 1,300 scientific posters presented at the ISSCR 2026 Annual Meeting in Montr...
Researchers evaluate whether hypoimmune cell engineering can help transplanted insulin-producing cells survive without chronic immunosuppression. The study aims to develop a cell replacement approach that can function without chronic immunosuppression, providing a curative therapy for people with type 1 diabetes.
The STEM-PD trial demonstrated the safety and feasibility of stem cell-derived dopaminergic cell transplantation in patients with moderate to advanced Parkinson's disease. The findings mark an important step in evaluating this approach as a potential treatment strategy for neurodegenerative diseases.
Researchers at ISSCR 2026 present interim clinical findings from the first Phase 1/2a trial of autologous iPSC-derived dopamine neuron precursor cells for Parkinson's disease. The approach uses each patient's own cells, and new genomic quality control methods ensure the manufactured cells are suitable for transplantation.
Early signs of clinical improvement have been observed in patients with treatment-resistant systemic sclerosis treated with investigational stem cell-derived CAR T-cell therapy, known as FT819. The therapy has demonstrated a reassuring safety profile and has the potential to expand access to patients who might otherwise face barriers t...
The REGEN4HD study marks a significant milestone in the development of regenerative medicine approaches for Huntington's disease. The Phase 1b/2a trial enrolls early-stage symptomatic patients to evaluate safety and tolerability.
A Phase 1/2a clinical study demonstrates long-term survival of transplanted human neural progenitor cells in patients with retinitis pigmentosa, maintaining a favorable safety profile. Visual acuity remained stable, and imaging showed cells remaining present in the subretinal space for at least one year.
Researchers present new insights into an iPSC-derived neural progenitor cell therapy for chronic ischemic stroke, demonstrating safety and biological activity over extended follow-up. The findings have the potential to expand treatment options for patients living with chronic stroke disability.
The International Society for Stem Cell Research convenes its 2026 Annual Meeting in Montréal, showcasing groundbreaking discoveries and emerging clinical advances. The meeting features nearly 1,300 scientific posters and presentations spanning every area of stem cell research.
Encellin reports non-fibrotic engraftment and host vascularization in Phase 1 trial participants, building on interim results. The findings support the company's approach to deliver cell therapy safely and durably without immunosuppression.
A recent study published in Stem Cell Reports found that prenatal high fructose exposure impairs fetal brain stem cell function, leading to long-lasting effects on learning and memory. The researchers discovered distinct epigenetic changes in fetal neural stem cells that persisted into adulthood, affecting gene expression and adult neu...
Researchers have developed vascular organoid patches that can regenerate microvessels in the heart, leading to improved heart function and reduced progression of coronary artery disease. The patches were shown to survive for several weeks and stimulate new microvessel formation, providing a potential treatment for ischemic heart disease.
The project aims to systematically map how individual pairs of cells influence each other, with the goal of understanding cell-cell communication in health and disease. By characterizing the cellular dyad, scientists can determine which cell influenced which partner, when the interaction began and what changed as a result.
Researchers found cytoskeletal proteins in cell nuclei of neural stem cells, influencing developmental programs. MAP1B protein helps maintain stem cell state for longer, contributing to abnormal brain development.
The International Society for Stem Cell Research announces the launch of a global consortium focused on integrating human stem cell-derived models into preclinical drug development. Bayer is a founding member, aiming to establish standardized frameworks and regulatory guidance for these models.
Researchers successfully generated rat-derived kidneys in mice using interspecies blastocyst complementation, demonstrating potential for growing transplantable human organs in larger animals. The study represents an important step toward addressing global kidney shortages.
Researchers at Stanford University found that electrical pulses can significantly extend the lifespan of sea squirts by rejuvenating their stem cells. The treatment causes a "reboot and rebound" of gene activity, similar to effects observed in humans after stress and exercise, leading to improved health and longevity.
Researchers have discovered a link between tooth aging and the decline of dental pulp stem cells' regenerative capacity. A unique subset of DPSCs, expressing NFATC1 protein, is essential for tooth regeneration. Eliminating this subset can lead to senescence and reduced ability to regenerate after injury.
Researchers developed cardiac organoids to address limitations of cell-based therapies in myocardial infarction. These three-dimensional tissue constructs integrate into host tissue, improve cardiac function, and reduce scar size without arrhythmogenic effects.
The ISSCR Consortium supports the FDA's draft guidance on using new approach methodologies (NAMs) in drug development, emphasizing the need for a flexible and science-driven framework. The consortium recommends clarifying biological complexity alignment with context of use and expanding recognition of computational modeling and hybrid ...
ISSCR 2027 will bring together scientists, industry leaders, and students to discuss breakthroughs in development, regeneration, AI, and bioengineering. The meeting emphasizes scientific exchange and career development through networking events and mentoring opportunities.
A recent study by Dr. Walaa Oweis and Prof. Eran Meshorer found that protein clumps in the brain may actually be protecting neurons from stress, acting as a vital quarantine system.
Researchers discovered that early-stage ectoderm cells are especially susceptible to SARS-CoV-2 infection, with heightened vulnerability driven by elevated TMPRSS2 activity and thinner glycocalyx. This raises concerns about potential developmental risks, particularly for infants born to mothers infected during early pregnancy.
The ISSCR emphasizes that continued investment in hESC research is essential to sustaining scientific progress and advancing life-saving therapies. Human embryonic stem cells remain a cornerstone of modern biomedical research due to their status as a gold standard for human pluripotency.
A new study uses a human stem cell-derived model to identify potential therapies for inflammatory bowel disease (IBD), highlighting glycyrrhizin as a promising candidate. Glycyrrhizin significantly prevents intestinal cell death in both stem cell models and mice with IBD, reducing inflammation and cell death.
Scientists at Karolinska Institutet have created a new method to produce insulin-producing cells from human stem cells, effectively regulating blood sugar levels in laboratory tests and reversing diabetes in mice. The optimized production process yields more mature and purer cells, demonstrating their potential for future treatments.
The Stem Cell Report podcast has marked five years of exploration in stem cell research, capturing significant progress in human development, disease, and regenerative medicine. The anniversary episode reunites past guests to discuss the field's evolution, highlighting advances in therapies, organoid systems, and global standards.
The ISSCR has elected Malin Parmar as vice president, bringing expertise in cellular neuroscience and regenerative therapies. The newly elected Board of Directors includes experts in engineering, biology, medicine, biomedical ethics, and public policy, who will guide the Society's global mission to advance excellence in stem cell science.
STEM Cell Reports has been named the official journal of the 2026 BaCell 3D Organoid Conference in Basel, Switzerland. The conference will bring together leading scientists and experts to share their latest findings on organoid technologies and disease modeling.
Researchers generated a comprehensive view of DNA methylation abnormalities in human MDS HSCs, uncovering a novel TET2-GFI1 axis that suppresses malignant transformation. The study identifies key hematopoietic regulators and provides a panoramic view of DNA methylation disruption in MDS.
Dr. Hongmei Wang joins Stem Cell Reports as an Associate Editor, bringing expertise in early embryo and placental development. Her laboratory investigates mechanisms governing embryonic and placental development, with potential for improving reproductive health outcomes.
A proposed embedded ethics approach facilitates ethically responsible research with human stem-cell-based embryo models by integrating continuous dialogue among scientists, ethicists, and regulators. This framework helps build trust and serves as a public policy tool to ensure that research meets both scientific and societal values.
The International Society for Stem Cell Research's official journal has implemented enhanced measures to strengthen scientific rigor and reproducibility in published research. New requirements include a completed ISSCR Standards Checklist shared with peer reviewers, ensuring critical experimental details are fully disclosed. All manusc...
A global clinical trial led by SickKids has found that mavacamten improves blood flow and reduces obstruction in youth with hypertrophic cardiomyopathy (HCM), a genetic heart disease. The study's results offer hope to families avoiding open-heart surgery, setting the stage for precision therapeutics.
The International Society for Stem Cell Research has named Stem Cell Reports as the official conference journal for the Latest Advances in Stem Cell-Based Disease Modelling and Drug Screening meeting. The journal will focus on high-impact research spanning basic discovery to clinical translation in stem cell science.
The FDA has approved a gene therapy for severe leukocyte adhesion deficiency-I, a rare genetic condition that affects one in a million children globally. The therapy, Kresladi, has been shown to significantly reduce severe infections and improve immune function in treated patients.
Researchers will use human stem cell-based models to uncover molecular and cellular mechanisms underlying autism and schizophrenia. They aim to identify genetic variants that alter brain development and pinpoint common underlying mechanisms for both conditions.
Researchers at UCLA have developed a novel immunotherapy that uses CAR-NKT cell therapy to fight endometrial cancer. The therapy achieved complete tumor elimination and prolonged survival in mouse models, outperforming conventional CAR-T cell therapies.
The ISSCR has launched a new continuing education course on stem cell therapies for Parkinson’s disease, addressing the need for clinicians to provide accurate information on emerging treatments. The course features expert faculty and patient perspectives, and is available through a free and paid pathway.
Researchers demonstrate that genetically engineered human pluripotent stem cells can overcome immune rejection in mice, surviving for five months with humanized immune systems. The findings provide proof-of-principle for a potential universal donor hPSC line designed to resist immune attack.
Researchers at Kyoto University developed mRNA therapy that successfully restored sperm production and enabled healthy offspring birth in genetically infertile male mice. The therapy targets genetic defects linked to male infertility, demonstrating a potential treatment for human infertility cases.
The ISSCR recognizes Dr. Kyle M. Loh's groundbreaking work on human pluripotent stem cells, enabling precision differentiation of various cell types and bridging stem cell biology and virology. His research has far-reaching implications for developmental biology, disease modeling, and regenerative medicine.
Dr. Alexander Meissner, Director at the Max Planck Institute for Molecular Genetics, has been named recipient of the 2026 ISSCR Momentum Award for his sustained scientific contributions to developmental and stem cell epigenetics. He will present his work at ISSCR 2026 in Montréal.
Stem Cell COREdinates and CorEUstem have transformed the global infrastructure of pluripotent stem cell research by uniting 79 core facilities across continents to advance collaboration, rigor, inclusivity, and innovation. Their shared standards and protocols have strengthened reproducibility and ensured excellence in accessible for in...
The International Society for Stem Cell Research has awarded the 2026 ISSCR Lifetime Achievement Award to Dr. Allen Eaves and late Dr. Connie Eaves, recognizing their groundbreaking work on blood stem cell biology, leukemia, and cancer stem cells. Their research and mentorship have profoundly influenced the field of stem cell science.